JP2017525354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525354A5 JP2017525354A5 JP2017505807A JP2017505807A JP2017525354A5 JP 2017525354 A5 JP2017525354 A5 JP 2017525354A5 JP 2017505807 A JP2017505807 A JP 2017505807A JP 2017505807 A JP2017505807 A JP 2017505807A JP 2017525354 A5 JP2017525354 A5 JP 2017525354A5
- Authority
- JP
- Japan
- Prior art keywords
- cell death
- high affinity
- programmed cell
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 63
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 63
- 229920001184 polypeptide Polymers 0.000 claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- 102220496972 Platelet-activating factor acetylhydrolase 2, cytoplasmic_K53T_mutation Human genes 0.000 claims 18
- 102220058921 rs786202731 Human genes 0.000 claims 18
- 102200118229 rs34665886 Human genes 0.000 claims 17
- 102220161672 rs148219510 Human genes 0.000 claims 13
- 102220586093 Homeobox protein DLX-1_V39R_mutation Human genes 0.000 claims 10
- 102220354149 c.289C>A Human genes 0.000 claims 10
- 102220568823 Dual specificity mitogen-activated protein kinase kinase 1_G65V_mutation Human genes 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 9
- 102220249043 rs145159429 Human genes 0.000 claims 9
- 102220226094 rs17217723 Human genes 0.000 claims 9
- 102220311149 rs41271047 Human genes 0.000 claims 9
- 102220279022 rs955258267 Human genes 0.000 claims 9
- 102220507725 GTP-binding protein RAD_Q66P_mutation Human genes 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 7
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 7
- 102220585589 Short-chain dehydrogenase/reductase family 42E member 1_Q63P_mutation Human genes 0.000 claims 7
- 102220361097 c.307C>T Human genes 0.000 claims 5
- 230000003278 mimic effect Effects 0.000 claims 5
- 102220013742 rs397516741 Human genes 0.000 claims 5
- 102220257864 rs1050971384 Human genes 0.000 claims 4
- 102220198136 rs1057519882 Human genes 0.000 claims 4
- 102200116701 rs115206969 Human genes 0.000 claims 4
- 102220250913 rs1364636517 Human genes 0.000 claims 4
- 102220624338 Interferon alpha-8_T51A_mutation Human genes 0.000 claims 3
- 102220492589 Protein numb homolog_S48D_mutation Human genes 0.000 claims 3
- 102220477170 Y-box-binding protein 2_S102A_mutation Human genes 0.000 claims 3
- 102220364119 c.148C>A Human genes 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 3
- 102200007406 rs148775298 Human genes 0.000 claims 3
- 102200017902 rs267606847 Human genes 0.000 claims 3
- 102220252689 rs373178770 Human genes 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102220492635 Integrin alpha-3_D52Y_mutation Human genes 0.000 claims 2
- 102100040418 Tumor protein D52 Human genes 0.000 claims 2
- 102220555263 Tumor protein D52_D52Y_mutation Human genes 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102220487428 Actin-related protein 2/3 complex subunit 3_R90K_mutation Human genes 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 229940123189 CD40 agonist Drugs 0.000 claims 1
- 108010062802 CD66 antigens Proteins 0.000 claims 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000037581 Persistent Infection Diseases 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 102220349284 c.287A>T Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- 102200160087 rs1131692231 Human genes 0.000 claims 1
- 102220126393 rs886044243 Human genes 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462035316P | 2014-08-08 | 2014-08-08 | |
| US62/035,316 | 2014-08-08 | ||
| US201562150789P | 2015-04-21 | 2015-04-21 | |
| US62/150,789 | 2015-04-21 | ||
| PCT/US2015/044356 WO2016022994A2 (en) | 2014-08-08 | 2015-08-07 | High affinity pd-1 agents and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525354A JP2017525354A (ja) | 2017-09-07 |
| JP2017525354A5 true JP2017525354A5 (enExample) | 2018-09-13 |
| JP6945444B2 JP6945444B2 (ja) | 2021-10-06 |
Family
ID=55264785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505807A Active JP6945444B2 (ja) | 2014-08-08 | 2015-08-07 | 高親和性ｐｄ−１薬剤とその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US10800830B2 (enExample) |
| EP (2) | EP3699189A1 (enExample) |
| JP (1) | JP6945444B2 (enExample) |
| CN (1) | CN107108707A (enExample) |
| CA (1) | CA2994927A1 (enExample) |
| CY (1) | CY1123385T1 (enExample) |
| DK (1) | DK3177640T3 (enExample) |
| ES (1) | ES2819451T3 (enExample) |
| HR (1) | HRP20201153T1 (enExample) |
| HU (1) | HUE050406T2 (enExample) |
| PL (1) | PL3177640T3 (enExample) |
| PT (1) | PT3177640T (enExample) |
| WO (1) | WO2016022994A2 (enExample) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2949648T3 (es) | 2012-12-20 | 2023-10-02 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| WO2016022994A2 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity pd-1 agents and methods of use |
| WO2016050721A1 (en) * | 2014-09-30 | 2016-04-07 | Intervet International B.V. | Pd-l1 antibodies binding canine pd-l1 |
| ES2941895T3 (es) | 2014-11-25 | 2023-05-26 | Bristol Myers Squibb Co | Métodos y composiciones para radioetiquetado con 18F del dominio de fibronectina tipo (III) |
| EP3702367B1 (en) | 2014-11-25 | 2024-05-15 | Bristol-Myers Squibb Company | Novel pd-l1 binding polypeptides for imaging |
| JP6336684B2 (ja) * | 2015-03-02 | 2018-06-06 | イノベイティブ セルラー セラピューティクス シーオー．，エルティディ．Ｉｎｎｏｖａｔｉｖｅ Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．，Ｌｔｄ． | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 |
| CR20170510A (es) * | 2015-04-10 | 2018-02-26 | Amgen Inc | Muteínas de interuquina 2 para la expansión de células t regulatorias |
| DK3283508T3 (en) | 2015-04-17 | 2021-05-31 | Alpine Immune Sciences Inc | Immunomodulatory Proteins with Tunable Affinities |
| JP2018515123A (ja) | 2015-05-18 | 2018-06-14 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| JP7014706B2 (ja) | 2015-07-13 | 2022-02-01 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法 |
| AU2016293674B2 (en) | 2015-07-16 | 2019-11-21 | Bioxcel Therapeutics, Inc. | A novel approach for treatment of cancer using immunomodulation |
| SG10202101909RA (en) | 2015-08-07 | 2021-04-29 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
| EP3352800B1 (en) | 2015-09-24 | 2022-01-05 | The University of North Carolina at Chapel Hill | Methods and compositions for reducing metastases |
| WO2017087885A1 (en) | 2015-11-19 | 2017-05-26 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers |
| WO2017177149A2 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| KR20250095754A (ko) | 2016-04-15 | 2025-06-26 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
| EP3443000B1 (en) | 2016-04-15 | 2025-11-12 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| US11352413B2 (en) * | 2016-05-17 | 2022-06-07 | Albert Einstein College Of Medicine | Engineered PD-1 variants |
| CN109562195A (zh) | 2016-06-01 | 2019-04-02 | 百时美施贵宝公司 | 用pd-l1结合多肽进行pet成像 |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| RU2656181C1 (ru) * | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Анти-pd-1-антитела, способ их получения и способ применения |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN118085109A (zh) | 2016-08-11 | 2024-05-28 | 昆士兰医学研究所理事会 | 免疫调节化合物 |
| WO2018067361A1 (en) * | 2016-10-04 | 2018-04-12 | The Curators Of The University Of Missouri | Peptides for molecular detection of pd-l1 |
| IL292551B2 (en) | 2016-10-07 | 2023-10-01 | Tcr2 Therapeutics Inc | Preparations and methods for reprogramming T-cell receptors using fusion proteins |
| AR110017A1 (es) | 2016-11-02 | 2019-02-13 | Jounce Therapeutics Inc | Anticuerpos de pd-1 y usos de estos |
| AU2017359450A1 (en) | 2016-11-09 | 2019-05-30 | HealthTell, Inc. | Coatings with tunable amine density |
| CN116514861A (zh) | 2016-11-09 | 2023-08-01 | 库博科学公司 | 预组装的、受保护的、化学稳定的化学选择性接头 |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| MX389083B (es) | 2016-12-01 | 2025-03-20 | Regeneron Pharma | Anticuerpos anti-pd-l1 radiomarcados para imagenes de inmuno-pet. |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| PL3565828T3 (pl) | 2017-01-05 | 2022-04-04 | Kahr Medical Ltd. | Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania |
| DK3565579T3 (da) * | 2017-01-05 | 2023-09-04 | Kahr Medical Ltd | Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf |
| WO2018127916A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-cd70 fusion protein and methods of use thereof |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| MX2019009565A (es) | 2017-02-10 | 2020-02-24 | Regeneron Pharma | Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet. |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| JP7386083B2 (ja) | 2017-03-16 | 2023-11-24 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｄ８０バリアント免疫調節タンパク質及びその使用 |
| AU2018235835A1 (en) | 2017-03-16 | 2019-09-05 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
| KR102653567B1 (ko) * | 2017-03-28 | 2024-04-02 | 오하이오 스테이트 이노베이션 파운데이션 | 인간 pd1 펩티드 백신 및 이의 용도 |
| WO2018192443A1 (zh) * | 2017-04-17 | 2018-10-25 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种多肽及其应用 |
| JP2020517259A (ja) | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| CN111432828A (zh) * | 2017-05-26 | 2020-07-17 | 约翰霍普金斯大学 | 用以调节免疫耐受的多功能抗体-配体捕获剂 |
| US10730944B2 (en) | 2017-07-24 | 2020-08-04 | Regeneron Pharmaceuticals, Inc. | Anti-CD8 antibodies and uses thereof |
| US20200206344A1 (en) * | 2017-08-21 | 2020-07-02 | Dana-Farber Cancer Institute, Inc. | Methods for modulating the interaction between ews-fli1 and baf complexes |
| KR102758545B1 (ko) | 2017-10-10 | 2025-01-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| SI3697817T1 (sl) | 2017-10-18 | 2023-01-31 | Forty Seven, Inc. | Terapija za raka jajčnikov na osnovi sredstva proti CD47 |
| TW202500579A (zh) | 2017-10-18 | 2025-01-01 | 美商艾爾潘免疫科學有限公司 | 變異型icos 配位體免疫調節蛋白及相關組合物及方法 |
| CN107916255B (zh) * | 2017-11-16 | 2021-06-04 | 复旦大学 | Pdl-1基因靶向特异性甲基化表观遗传修饰抗肿瘤分子及其用途 |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| TW201940182A (zh) | 2018-01-22 | 2019-10-16 | 美商安德賽特公司 | Car t 細胞之使用方法 |
| JP2021512166A (ja) | 2018-01-30 | 2021-05-13 | フォグホーン セラピューティクス インコーポレイテッドＦｏｇｈｏｒｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 化合物及びその使用 |
| CA3090089A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| US12473336B2 (en) | 2018-02-21 | 2025-11-18 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses thereof |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| CN108794619B (zh) * | 2018-05-31 | 2021-09-17 | 郑州大学 | 一种高亲和pd-1蛋白突变体 |
| WO2019227490A1 (en) * | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| MX2020012613A (es) | 2018-06-01 | 2021-04-13 | Tayu Huaxia Biotech Medical Group Co Ltd | Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones. |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| CN112543773B (zh) | 2018-07-11 | 2024-05-31 | 卡尔医学有限公司 | SIRPα-4-1BBL变体融合蛋白及其使用方法 |
| KR20210044221A (ko) | 2018-07-11 | 2021-04-22 | 카 메디컬 리미티드 | Pd1-4-1bbl 변이체 융합 단백질 및 이의 사용 방법 |
| CN108997492B (zh) * | 2018-07-19 | 2022-04-12 | 海珂分子（北京）科技有限责任公司 | 高亲和力的pd1胞外区突变体多肽及相关融合蛋白 |
| TW202348622A (zh) * | 2018-09-14 | 2023-12-16 | 李蘭 史丹佛學院理事會 | sPD-1變異體 – FC融合蛋白 |
| US12390541B2 (en) * | 2018-09-26 | 2025-08-19 | Albert Einstein College Of Medicine | Mutant variants of PD-1 receptor with selective binding to PD-L1 and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US20220010301A1 (en) * | 2018-11-14 | 2022-01-13 | Cowper Sciences Inc. | Methods of selecting functional interface mimics, and compositions thereof |
| IL283165B2 (en) | 2018-11-21 | 2024-12-01 | Mayo Found Medical Education & Res | Adenoviruses and methods for using adenoviruses |
| CN111100199B (zh) * | 2018-12-29 | 2021-02-12 | 北京百普赛斯生物科技股份有限公司 | 一种荧光素标记的蛋白四聚体及其制备方法与应用 |
| CN113795511B (zh) | 2019-01-23 | 2024-07-23 | 大有华夏生物医药集团有限公司 | 抗pd-l1双抗体及其用途 |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020160100A1 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN111714618B (zh) * | 2019-03-22 | 2024-07-12 | 香雪生命科学技术（广东）有限公司 | T细胞和高亲和力pd-1融合蛋白的组合 |
| CN110054701B (zh) * | 2019-04-17 | 2022-12-27 | 中国医学科学院血液病医院（血液学研究所） | 一种基于间充质干细胞的抗肿瘤靶向给药系统及其应用 |
| IL292788B2 (en) | 2019-04-29 | 2023-12-01 | Mayo Found Medical Education & Res | Multivalent pd-l1 binding compounds for treating cancer |
| SG11202111360YA (en) | 2019-05-01 | 2021-11-29 | Juno Therapeutics Inc | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
| CA3136742A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
| BR112021024003A2 (pt) | 2019-05-31 | 2022-04-19 | Alx Oncology Inc | Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico |
| CN112279923B (zh) * | 2019-07-22 | 2023-07-18 | 南京助天中科科技发展有限公司 | 一种嵌合抗原受体及其应用 |
| AU2020381514A1 (en) * | 2019-11-14 | 2022-06-02 | Ludwig Institute For Cancer Research Ltd | Compositions and methods for immunotherapy |
| WO2021108693A1 (en) | 2019-11-27 | 2021-06-03 | ALX Oncology Inc. | Combination therapies for treating cancer |
| JP7650047B2 (ja) * | 2019-11-27 | 2025-03-24 | 株式会社 MiyaCare Therapeutics | 変異型結合性タンパク質の製造方法及び変異型ｐｄ－１ |
| WO2021155262A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12473349B2 (en) | 2020-05-06 | 2025-11-18 | Korea University Research And Business Foundation | PD-1 variants having increased PD-L1 affinity |
| KR102623161B1 (ko) * | 2020-10-08 | 2024-01-09 | 고려대학교 산학협력단 | Pd-l1 친화도가 증가된 pd-1 변이체 |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US20230218777A1 (en) * | 2020-05-28 | 2023-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Aerosolized mucus-tethering nanobodies to protect against viral and microbial contamination in closed and semi-enclosed spaces |
| JP2023531531A (ja) | 2020-06-26 | 2023-07-24 | ジュノ セラピューティクス ゲーエムベーハー | 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法 |
| US20230414660A1 (en) * | 2020-11-13 | 2023-12-28 | Ludwig Institute For Cancer Research Ltd | Pd-1 decoy variants for immunotherapy |
| CN112999368A (zh) * | 2021-04-09 | 2021-06-22 | 广东药康生物科技有限公司 | 人源化模型进行药效评价方法的建立 |
| US12098214B2 (en) | 2021-05-13 | 2024-09-24 | ALX Oncology Inc. | Combination therapies for treating cancer |
| EP4436615A1 (en) * | 2021-11-26 | 2024-10-02 | Vita Therapeutics, Inc. | Immune cell therapy of pd-l1 positive cancers |
| CN117777303A (zh) * | 2022-09-27 | 2024-03-29 | 北京大学 | 一种高亲和力pd1蛋白偶联物及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| AU687829B2 (en) | 1993-06-24 | 1998-03-05 | Advec, Inc. | Adenovirus vectors for gene therapy |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| JPH07291996A (ja) * | 1994-03-01 | 1995-11-07 | Yuu Honshiyo | ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物 |
| EP1083231A1 (en) | 1999-09-09 | 2001-03-14 | Introgene B.V. | Smooth muscle cell promoter and uses thereof |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| US7332567B2 (en) | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
| US7169874B2 (en) | 2001-11-02 | 2007-01-30 | Bausch & Lomb Incorporated | High refractive index polymeric siloxysilane compositions |
| AU2006265108C1 (en) * | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| MX2011002250A (es) | 2008-08-25 | 2011-08-17 | Amplimmune Inc | Antagonistas de muerte celular programada-1 y métodos de uso de los mismos. |
| HUE027525T2 (en) * | 2008-08-25 | 2016-11-28 | Amplimmune Inc | PD-1 Antagonist preparations and their use |
| US9598491B2 (en) | 2008-11-28 | 2017-03-21 | Emory University | Methods for the treatment of infections and tumors |
| US20110189743A1 (en) * | 2009-10-06 | 2011-08-04 | Bio Architecture Lab, Inc. | Microbial systems for producing commodity chemicals |
| EP2638061B1 (en) | 2010-11-11 | 2015-04-22 | The University of Hong Kong | Soluble pd-1 variants, fusion constructs, and uses thereof |
| CN103561771B (zh) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
| RS57324B1 (sr) * | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antitela i drugi molekuli koji vezuju b7-h1 i pd-1 |
| JP6238459B2 (ja) * | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| US8956619B2 (en) * | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| JP6460796B2 (ja) | 2012-01-17 | 2019-01-30 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 高親和性ｓｉｒｐ−アルファ試薬 |
| AU2013211824B2 (en) * | 2012-01-27 | 2017-06-01 | Gliknik Inc. | Fusion proteins comprising IgG2 hinge domains |
| KR102247979B1 (ko) | 2012-05-25 | 2021-05-04 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| US9845356B2 (en) * | 2012-08-03 | 2017-12-19 | Dana-Farber Cancer Institute, Inc. | Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use |
| SG11201502598SA (en) | 2012-10-02 | 2015-05-28 | Sloan Kettering Inst Cancer | Compositions and methods for immunotherapy |
| EP3575326B8 (en) | 2012-12-17 | 2022-05-25 | Trillium Therapeutics ULC | Treatment of cd47+ disease cells with sirp alpha-fc fusions |
| WO2014124217A1 (en) | 2013-02-07 | 2014-08-14 | Albert Einstein College Of Medicine Of Yeshiva University | A selective high-affinity immune stimulatory reagent and uses thereof |
| HRP20201419T1 (hr) | 2013-02-26 | 2020-12-11 | Memorial Sloan Kettering Cancer Center | Pripravci i postupci za imunoterapiju |
| WO2016022994A2 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity pd-1 agents and methods of use |
| JP7064234B2 (ja) * | 2015-05-18 | 2022-05-10 | エービー イニチオ バイオセラピューティクス，インク． | Ｓｉｒｐポリペプチド組成物および使用の方法 |
-
2015
- 2015-08-07 WO PCT/US2015/044356 patent/WO2016022994A2/en not_active Ceased
- 2015-08-07 EP EP20166891.0A patent/EP3699189A1/en active Pending
- 2015-08-07 US US15/502,439 patent/US10800830B2/en active Active
- 2015-08-07 PL PL15829652T patent/PL3177640T3/pl unknown
- 2015-08-07 EP EP15829652.5A patent/EP3177640B1/en active Active
- 2015-08-07 CA CA2994927A patent/CA2994927A1/en active Pending
- 2015-08-07 HU HUE15829652A patent/HUE050406T2/hu unknown
- 2015-08-07 PT PT158296525T patent/PT3177640T/pt unknown
- 2015-08-07 US US14/821,589 patent/US9546206B2/en active Active
- 2015-08-07 ES ES15829652T patent/ES2819451T3/es active Active
- 2015-08-07 DK DK15829652.5T patent/DK3177640T3/da active
- 2015-08-07 CN CN201580054333.5A patent/CN107108707A/zh active Pending
- 2015-08-07 JP JP2017505807A patent/JP6945444B2/ja active Active
- 2015-08-07 HR HRP20201153TT patent/HRP20201153T1/hr unknown
- 2015-11-03 US US14/931,725 patent/US9562087B2/en active Active
-
2020
- 2020-05-26 US US16/883,396 patent/US11814419B2/en active Active
- 2020-08-05 CY CY20201100728T patent/CY1123385T1/el unknown
-
2023
- 2023-10-06 US US18/482,223 patent/US20240174729A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017525354A5 (enExample) | ||
| Xiang et al. | Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2 | |
| Leneva et al. | Architecture and mechanism of metazoan retromer: SNX3 tubular coat assembly | |
| Kato et al. | Structural analysis of RIG-I-like receptors reveals ancient rules of engagement between diverse RNA helicases and TRIM ubiquitin ligases | |
| Chen et al. | A DDX6-CNOT1 complex and W-binding pockets in CNOT9 reveal direct links between miRNA target recognition and silencing | |
| Liu et al. | A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection | |
| Peng et al. | Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody | |
| Chi et al. | An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants | |
| Li et al. | A molecular-level account of the antigenic hantaviral surface | |
| Ketema et al. | Requirements for the localization of nesprin-3 at the nuclear envelope and its interaction with plectin | |
| Burgo et al. | A molecular network for the transport of the TI-VAMP/VAMP7 vesicles from cell center to periphery | |
| Friedrich et al. | DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety | |
| van Dinther et al. | Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling | |
| Li et al. | Structural basis of nectin-1 recognition by pseudorabies virus glycoprotein D | |
| Håberg et al. | SNX18 is an SNX9 paralog that acts as a membrane tubulator in AP-1-positive endosomal trafficking | |
| Hong et al. | Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants | |
| Wu et al. | LMP1 protein from the Epstein-Barr virus is a structural CD40 decoy in B lymphocytes for binding to TRAF3 | |
| Tousley et al. | Huntingtin associates with the actin cytoskeleton and α-actinin isoforms to influence stimulus dependent morphology changes | |
| Van Roeyen et al. | Cold shock Y-box protein-1 proteolysis autoregulates its transcriptional activities | |
| Fournier et al. | Recruitment of RED-SMU1 complex by Influenza A Virus RNA polymerase to control Viral mRNA splicing | |
| Collins et al. | The structure of the GGA1-GAT domain reveals the molecular basis for ARF binding and membrane association of GGAs | |
| HRP20201153T1 (hr) | Pd-1 sredstva visokog afiniteta i načini uporabe | |
| JP2018519296A5 (enExample) | ||
| Mohamed et al. | The CRL4DCAF1 cullin‐RING ubiquitin ligase is activated following a switch in oligomerization state | |
| Tachibana et al. | Tight junction modulating bioprobes for drug delivery system to the brain: a review |